An economic evaluation modeled combinations of maternal RSV vaccination and infant nirsevimab to prevent severe RSV in the first season of life. Maternal vaccination plus targeted nirsevimab in selected high-risk scenarios reduced hospitalizations and was cost-effective compared with no intervention across a range of assumptions. These findings inform policy decisions on how to sequence and combine biologics and vaccines in routine infant care. To read more Click Here ##Reference## Taleshi J, Paramo MV, Watts A, et al.
Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada. Vaccine. 2025;68:127936.## In your experience, which RSV prevention approach is most feasible to scale first in routine pediatric practice Universal maternal vaccination Universal infant nirsevimab Risk-based nirsevimab only Seasonal non-pharmacologic measures alone
